EGFR and non-small cell lung carcinoma: In the LUX-Lung 7 study, PFS of patients with advanced NSCLC with common EGFR mutations was longer with afatinib than with gefitinib (11.0 vs. 10.9 months; HR = 0.73, 95% CI = 0.57–0.95, p = 0.017) [9].